Pharmaceutical company Pharmaxis recently announced positive results in its recently completed Phase II trial of Bronchitol  in children and adolescents with cystic fibrosis (CF). The trial, conducted across 39 global centres, met its primary endpoint and confirms that Bronchitol is efficacious in young patients. Trial participants had a significant improvement in lung function compared to placebo

Download full release>